TWEAK/Fn14 signaling drives oxidative cardiac injury in systemic lupus erythematosus: Evidence from patient biomarker studies, lupus mouse models, and cardiomyocyte assays.

Yale Liu; Yan Zhu; Xueting Peng; Meixuan Li; Juan Wang; Yan Zhang; Xiaoqian Hu; Mingzhu Zhou; Kaixuan Ren; Dan Zhang; Xinyi Guo; Yumin Xia; Huanhuan Huo

doi:10.1002/art.70110

February 26, 2026

TWEAK/Fn14 signaling drives oxidative cardiac injury in systemic lupus erythematosus: Evidence from patient biomarker studies, lupus mouse models, and cardiomyocyte assays.

View at Publisher

Ask AI

Bookmark

Share

Key Points

To investigate the role of TWEAK/Fn14 signaling in oxidative cardiac injury associated with systemic lupus erythematosus.
Analysis of patient biomarkers related to TWEAK/Fn14 signaling
Use of lupus mouse models to study cardiac injury mechanisms
In vitro cardiomyocyte assays to assess oxidative stress effects
Identified increased oxidative stress markers in cardiac tissues of lupus patients
Demonstrated that TWEAK/Fn14 signaling contributes significantly to cardiomyocyte injury
Proposed TWEAK/Fn14 as a promising biomarker and target for therapeutic interventions.

Implication

Demonstrates oxidative cardiomyocyte injury in systemic lupus erythematosus, indicating TWEAK/Fn14 as a therapeutic target.

Abstract

TWEAK/Fn14 signaling drives oxidative stress- mediated cardiomyocyte injury in SLE and represents a promising biomarker and therapeutic target for lupus-associated cardiac damage.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/69a287010a974eb0d3c025d2 https://doi.org/10.1002/art.70110

View at Publisher

Ask AI

Bookmark

Share

TWEAK/Fn14 signaling drives oxidative cardiac injury in systemic lupus erythematosus: Evidence from patient biomarker studies, lupus mouse models, and cardiomyocyte assays.

Key Points

Implication

Abstract

Discussion

Cite This Study

TWEAK/Fn14 signaling drives oxidative cardiac injury in systemic lupus erythematosus: Evidence from patient biomarker studies, lupus mouse models, and cardiomyocyte assays.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers